Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study.

ABSTRACT:

Context

People infected with HIV have a higher risk for developing insulin resistance, diabetes, and cardiovascular disease than the general population. Dipeptidyl peptidase IV (DPP4) inhibitors are glucose-lowering medications with pleiotropic actions that may particularly benefit people with HIV, but the immune and virological safety of DPP4 inhibition in HIV is unknown.

Objective

DPP4 inhibition will not reduce CD4+ T lymphocyte number or increase HIV viremia in HIV-positive adults.

Design

This was a randomized, placebo-controlled, double-blind safety trial of sitagliptin in HIV-positive adults.

Setting

The study was conducted at an academic medical center.

Participants

Twenty nondiabetic HIV-positive men and women (9.8 ± 5.5 years of known HIV) takin

SUBMITTER: Goodwin SR 

PROVIDER: S-EPMC3565112 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature